Journal
CURRENT CANCER DRUG TARGETS
Volume 7, Issue 3, Pages 209-215Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/156800907780618266
Keywords
inflammation; pancreatic cancer; glycogen synthase kinase
Categories
Funding
- Medical Research Council [G0100872] Funding Source: researchfish
- Medical Research Council [G0100872] Funding Source: Medline
- MRC [G0100872] Funding Source: UKRI
Ask authors/readers for more resources
Glycogen synthase kinase (GSK) was initially described as a key enzyme involved in glycogen metabolism. However, since that time it has been found to regulate a diverse range of cell functions. In addition to having a major role in the regulation of the important onco-protein beta-catenin, GSK is also a critical regulator of NF-kappa B. NF-kappa B comprises a family of transcription factors which activate the expression of a wide array of genes involved in inflammation, tumourigenesis, metastasis, differentiation, embryonic development, apoptosis. Inflammation mediated by the NF-kappa B family has been implicated in the initiation of pancreatic cancer, resistance to chemotherapy and the development of the debilitating cancer cachexia seen with advanced disease. Hence, GSK has potential as an important new target both in the treatment of resectable pancreatic cancer as an adjuvant to surgery, and in the palliation of inoperable tumours.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available